Holen Sie sich die Stockscreener-App
7.82
4.28%
-0.35
Handel nachbörslich:
8.21
0.39
+4.99%
Schlusskurs vom Vortag:
$8.17
Offen:
$8.45
24-Stunden-Volumen:
1.18M
Relative Volume:
2.12
Marktkapitalisierung:
$933.36M
Einnahmen:
$58.49M
Nettoeinkommen (Verlust:
$-105.04M
KGV:
-6.5953
EPS:
-1.1857
Netto-Cashflow:
$-13.78M
1W Leistung:
-13.50%
1M Leistung:
-20.85%
6M Leistung:
-28.65%
1J Leistung:
-9.91%
1-Tages-Spanne:
$7.80
$8.57
1-Wochen-Bereich:
$7.80
$8.96
52-Wochen-Spanne:
$7.80
$13.77
Immatics N V Stock (IMTX) Company Profile
Vergleichen Sie IMTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| IMTX | 7.82 | 933.36M | 58.49M | -105.04M | -13.78M | -1.1857 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-03-24 | Eingeleitet | Bryan Garnier | Buy |
| 2020-11-20 | Eingeleitet | BofA Securities | Buy |
| 2020-09-22 | Eingeleitet | Goldman | Buy |
| 2020-07-27 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-24 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Immatics N V Aktie (IMTX) Neueste Nachrichten
Immatics NV earnings beat by €0.14, revenue topped estimates - Investing.com UK
Immatics: Q3 Earnings Snapshot - Milford Mirror
Immatics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Immatics reports Q3 EPS (EUR 0.11) vs. (EUR 0.32) last year - TipRanks
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Immatics announces clinical data on TCER IMA402 targeting PRAME - TipRanks
Immatics sees cash runway into 2H27 - TipRanks
Immatics Announces Third Quarter 2024 Financial Results, - GlobeNewswire
T. Rowe Price Investment Management, Inc. Reduces Stake in Immatics NV - GuruFocus.com
Immatics (NASDAQ:IMTX) Reaches New 52-Week LowShould You Sell? - MarketBeat
When the Price of (IMTX) Talks, People Listen - Stock Traders Daily
Immatics N.V. Warrants (IMTXW) SEC Filing Summary - Quartzy
IMTX (Immatics NV) FCF Yield % : -4.41 (As of Nov. 11, 2024) - GuruFocus.com
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME - 新浪香港
Immatics Unveils Promising TCR-T Therapy Developments - TipRanks
Immatics Announces Multiple Presentations at the 39th - GlobeNewswire
Wellington Management Group LLP Increases Stake in Immatics NV - GuruFocus.com
Piper Sandler Initiates Coverage of Immatics N.V. (IMTX) with Overweight Recommendation - MSN
Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
232,900 Shares in Immatics (NASDAQ:IMTX) Bought by abrdn plc - MarketBeat
Objective long/short (IMTX) Report - Stock Traders Daily
Short Interest in Immatics (NASDAQ:IMTX) Expands By 5.3% - MarketBeat
Shareholders in Immatics (NASDAQ:IMTX) have lost 35%, as stock drops 6.3% this past week - Simply Wall St
Immatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50% - Yahoo Finance
Perceptive Advisors LLC Reduces Stake in Immatics NV - Yahoo Finance
Immatics N.V. Announces Major Share Offering - TipRanks
Market Update: Immatics N.V (IMTX) Sees Negative Movement, Closing at 9.30 - The Dwinnex
Immatics (NASDAQ:IMTX) Short Interest Update - MarketBeat
It makes sense and dollars to buy Immatics N.V (IMTX) stock - SETE News
206,920 Shares in Immatics (NASDAQ:IMTX) Bought by Cubist Systematic Strategies LLC - MarketBeat
Immatics: A Promising TCR Pipeline (NASDAQ:IMTX) - Seeking Alpha
Upstream catches aftermarket updraft, as Camp4 IPO gets muted reception - BioCentury
Immatics (NASDAQ:IMTX) Sees Large Volume IncreaseWhat's Next? - MarketBeat
A closer look at IMTX’s price-to-free cash flow ratio - US Post News
Ratio Analysis: Unpacking Immatics N.V (IMTX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Immatics Advances IMA203 to Phase 3 Trial in Melanoma - Yahoo Finance
Immatics Announces Pricing of $150 Million Public Offering - StockTitan
Immatics Off To Phase III With IMA203 After Positive Melanoma Results - Scrip
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday? - AOL
IMTX: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Immatics Announces Proposed $150 Million Public Offering - GlobeNewswire
Immatics (NASDAQ:IMTX) Shares Gap DownHere's What Happened - MarketBeat
Form 424B2 Immatics N.V. - StreetInsider.com
Immatics provides update on Phase 1b trial of ACTengine in melanoma - TipRanks
Form 6-K Immatics N.V. For: Oct 10 - StreetInsider.com
Immatics Announces Updated Phase 1b Clinical Data on - GlobeNewswire
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial - StockTitan
Immatics N.V. (IMTX) Receives Buy Rating from Analysts - Insider Monkey
Finanzdaten der Immatics N V-Aktie (IMTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):